GSK-364735

GSK‑364735 is a small molecule investigational drug developed as a potent inhibitor of human immunodeficiency virus type 1 (HIV‑1) integrase. It belongs to the naphthyridinone class and acts by blocking viral DNA integration into the host genome through interaction at the two-metal binding site within the catalytic center of HIV integrase. The compound demonstrated strong antiviral activity in vitro and in clinical studies, including efficacy against wild-type HIV and strains resistant to other antiretrovirals. Clinical development reached Phase II for HIV infection, but was discontinued due to adverse liver effects observed in long-term preclinical safety studies[1][2][3][5][8].

Other names

NaphthyridinoneUNII-SXN0KXT60SUNII-SXN-0KXT60SUNII-SXN 0KXT60SSXN0KXT60SSXN-0KXT60SSXN 0KXT60S863434-13-3